Chronic Lymphocytic Leukemia Clinical Trial
Safety and Efficacy of IDEC-152 in the Treatment of Chronic Lymphocytic Leukemia (CLL)
Summary
To determine what side effects and what clinical effects if any the administration of this investigational product, IDEC-152 (an antibody against CD23 which is an important protein on leukemia cells and certain cells in the body's immune system), has on the CLL patient population.
Eligibility Criteria
Inclusion Criteria:
Signed IRB-approved informed consent.
Greater than 18 years of age
Proof of CD23+ CLL or small lymphocytic lymphoma (SLL)
Progressive disease after at least 1 course of chemotherapy
Acceptable hematologic status, liver function, renal function, and pulmonary function
Patients of reproductive potential must agree to follow accepted birth control methods during treatment and for 3 months after completion of treatment
Exclusion Criteria:
Previous exposure to IDEC-152 or other anti-CD23 antibodies
Presence of HIV infection or AIDS
Serious nonmalignant disease
Active uncontrolled bacterial, viral or fungal infections.
Clinically active autoimmune disease
Pregnant or currently breast feeding
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
La Jolla California, , United States
LaJolla California, , United States
Baltimore Maryland, , United States
New Hyde Park New York, , United States
New York New York, , United States
Columbus Ohio, , United States
Houston Texas, , United States
How clear is this clinincal trial information?
Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.